USE OF SERUM SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TO IDENTIFY SEVERITY OF LIVER FIBROSIS AND ACTIVITY IN CHRONIC VIRAL HEPATITIS C PATIENTS
Journal: Indian Journal of Medical Research and Pharmaceutical Sciences (Vol.3, No. 1)Publication Date: 2016-01-30
Authors : Amir Helmy MD; Nevine I.Mousa MD; Mansour Nassef MD; Khaled A.Mansoor MD; Sherif H.Maroof MD; Abdelrahman Khedr MD; Dina Elshennawy MD; Mahmoud Nagiub MSc;
Page : 1-12
Keywords : : Ayurveda; Soluble Urokinase Plasminogen Activator Receptor(suPAR); Liver fibrosis; chronic hepatits C;
- USE OF SERUM SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TO IDENTIFY SEVERITY OF LIVER FIBROSIS AND ACTIVITY IN CHRONIC VIRAL HEPATITIS C PATIENTS
- Determining the Role of Serum Hyluronic Acid Levels to Degree of Fibrosis in Patients with Chronic Viral Hepatitis
- Serum YKL-40 (Chitinase-3-Like Protein 1) Compared to APRI and FIB-4 in Predicting Liver Fibrosis in Children with Chronic Hepatitis C
- Hepatic Steatosis And Necro-Inflammato ry Activity Overestimate Liver Stiffness by Transient Elastography in Staging Liver Fibrosis in Chronic Hepatitis C
- Increased Levels of TNF-α, IL-6, and IL-10 are Associated with The Degree of Liver Fibrosis in Chronic Hepatitis B Patients with NUC Therapy
Abstract
Background: identification of individuals with severe liver fibrosis among patients with chronic liver disease is of major importance when evaluating prognosis, potential risk for complications, and when deciding treatment strategies. Attempts to find reliable noninvasive markers of liver fibrosis are frequent to avoid the complications of liver biopsy. High serum concentrations of soluble urokinase plasminogen activator receptor (suPAR) are suggested to be involved in inflammation, tissue remodeling, and cancer metastasis. Objectives: To evaluate serum (suPAR) as a noninvasive biomarker to detect severity of liver fibrosis and activity in patients with chronic C hepatitis infection. Patients and Methods: 40 patients with chronic hepatitis (C) viral infection prior to treatment with antiviral combination therapy (Pegylated Interferon, Ribavirin and Sofosbuvir) were enrolled in the study.All patients were subjected to liver biopsy with assessment of serum(suPAR) levels . Result: There was significant rise in suPAR level in F4 (15.3±0.3 ng/ml ) compared to F3 (6.2±1.1 ng/ml) , F2 (4.0±1 ng/ml) and F1 (1.1±0.2 ng/ml) (P< 0.001).Also there was a significant rise in (suPAR) level in A2 (6.3±4.5 ng/ml) compared to A1 (1.1±0.2 ng/ml) (P< 0.001).There was a significant positive correlation between (suPAR) level with the stages of liver fibrosis(r=0.921, P< 0.001) and AFP (r=0.383, P< 0.018).On constructing receiver operating characteristics curve(ROC) for prediction of grade of activity, the cut-off value was ? 3.0 ng/mL can differentiate between moderate activity (A?2) and mild activity(A? 2). For prediction of different stages of liver fibrosis , it was found that cut-off value of (suPAR) for prediction of significant fibrosis F?2 was ? 2.0 ng/ml, advanced fibrosis F? 3 was ? 5.0 ng/ml, and of cirrhosis (F=4)was ?12 ng/ml. Conclusion: Serum levels suPAR can predict severity of liver fibrosis and activity in patients with chronic HCV infection
Other Latest Articles
- SURVEY OF REAL-TIME HEALTHCARE
- YET ANOTHER PROOF FOR BAUDHAYANA THEOREM (PYTHAGOREAN THEOREM) OR THE DIAGONAL LENGTH IN TERMS OF PI
- Sphenochoanal polyp a case report
- CASE REPORT OF DCR DONE IN A HCV POSITIVE PATIENT ON PACEMAKER
- TRAPEZOID SHAPED OMOHYOIDEUS MUSCLE: An Anatomic Variation seen in Functional Neck Dissection
Last modified: 2016-01-03 17:45:53